• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    11/4/24 11:49:14 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care
    Get the next $PETQ alert in real time by email
    SC 13G/A 1 UnitedStates_13G__PetIQIncUS.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) PetIQ Inc (Title of Class of Securities) Common Stock (CUSIP Number) 71639T106 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 71639T106 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 23,806 (7) Sole dispositive power 1,508,258 (8) Shared dispositive power 51,298 (9) Aggregate amount beneficially owned by each reporting person 1,559,556 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.25% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: PetIQ Inc Item 1(b) Address of issuer's principal executive offices: 230 East Riverside Drive Eagle, ID 83616 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 71639T106 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 1,559,556 (b) Percent of class: 5.25% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 1,559,556 (b) Percent of class: 5.25% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 23,806 (iii) Sole power to dispose or to direct the disposition of: 1,508,258 (iv) Shared power to dispose or to direct the disposition of: 51,298 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Hol
    Get the next $PETQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PETQ

    DatePrice TargetRatingAnalyst
    8/8/2024$30.00 → $31.00Buy → Hold
    Truist
    12/19/2023$22.00Buy
    Jefferies
    9/6/2023$28.00Buy
    Lake Street
    5/13/2022Outperform → Perform
    Oppenheimer
    3/3/2022$32.00 → $29.00Outperform
    Raymond James
    11/30/2021$30.00Buy
    The Benchmark Company
    11/30/2021$30.00Buy
    Benchmark
    11/4/2021$41.00 → $32.00Outperform
    Raymond James
    More analyst ratings

    $PETQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group

    EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group ("Bansk"), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the transaction. With the completion of the transaction, PetIQ shares no longer trade on and will be delisted from the Nasdaq stock exchange. PetIQ is now a privately held company and co

    10/25/24 8:45:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Results of Special Meeting of Stockholders

    EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the "Agreement") pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ's common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion. "On behalf of PetIQ's Board of Directors, we are excited to announce stockholders' approval of our proposed transaction with Bansk Group, repre

    10/22/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PetIQ downgraded by Truist with a new price target

    Truist downgraded PetIQ from Buy to Hold and set a new price target of $31.00 from $30.00 previously

    8/8/24 6:48:12 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Jefferies initiated coverage on PetIQ with a new price target

    Jefferies initiated coverage of PetIQ with a rating of Buy and set a new price target of $22.00

    12/19/23 6:55:11 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Lake Street initiated coverage on PetIQ with a new price target

    Lake Street initiated coverage of PetIQ with a rating of Buy and set a new price target of $28.00

    9/6/23 9:07:45 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:31 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:13 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:00:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    SEC Filings

    View All

    SEC Form 15-12G filed by PetIQ Inc.

    15-12G - PetIQ, Inc. (0001668673) (Filer)

    11/4/24 4:27:39 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:19:31 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:10:10 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Financials

    Live finance-specific insights

    View All

    PetIQ, Inc. Reports Second Quarter 2024 Financial Results

    Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ's Founder and CEO, commented, "We are very pleased to report another quarter of record financial results. The strength of PetIQ's brands fueled second quarter profitability that exceeded our expectati

    8/7/24 8:01:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

    EAGLE, Idaho, July 17, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the second quarter and six months ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, August 7, 2024. To listen to the live call participants in North America may dial 833-816-1410 and international participants may dial 412-317-0503. In addition, the call will be broadcast live

    7/17/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Reports First Quarter 2024 Financial Results

    Reports Record First Quarter 2024 Net Sales of $308.4 MillionAchieves Record First Quarter Net IncomeRecord Adjusted EBITDA Exceeds Company's First Quarter 2024 GuidanceRaises Full Year 2024 Outlook EAGLE, Idaho, May 08, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the first quarter ended March 31, 2024. Cord Christensen, PetIQ's Founder and CEO commented, "We've started 2024 off well with broad-based growth and strong pet parent demand for our product offerings. PetIQ's manufactured brands captured a disproportionate amount of their category market share to fuel

    5/8/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Leadership Updates

    Live Leadership Updates

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Appoints John Pearson to Executive Vice President, Services & Manufactured Products

    EAGLE, Idaho, Aug. 02, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced that John Pearson, who has served as the Company's Senior Vice President, Head of Services since 2022, has been appointed Executive Vice President, Services & Manufactured Products, a newly created role, effective August 2, 2023. In his new role, Pearson will gain responsibility for PetIQ's manufactured product portfolio, inclusive of the Company's sales and marketing teams, while maintaining his current responsibilities for the Services segment. Pearson will continue to report directly to Michael Smith, President and Chief Ope

    8/2/23 8:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Simple Mills Appoints Sheryl O'Loughlin to Board of Directors

    #1 Cookie, Cracker, and Baking Mix Brand in the Natural Channel Taps Industry Veteran to Provide Guidance in Innovation and Sustainability Simple Mills, the company on a mission to advance the holistic health of the planet and its people through delicious, better-for-you foods, today announced the addition of CPG industry veteran, Sheryl O'Loughlin, to its Board of Directors. O'Loughlin is an accomplished entrepreneur, CEO, author, and board member bringing extensive experience leading fast-growing, innovative consumer products companies. In her new role, O'Loughlin will provide strategic counsel and guidance to help support Simple Mills in scaling the company to the next level, creating o

    11/29/22 8:03:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/14/24 6:36:50 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/12/24 5:02:29 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/4/24 11:49:14 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care